VBI Vaccines Inc.
VBIV · NASDAQ
3/31/2024 | 12/31/2023 | 9/30/2023 | 6/30/2023 | |
|---|---|---|---|---|
| Revenue | $1,214 | $853 | $6,624 | $720 |
| % Growth | 42.3% | -87.1% | 820% | – |
| Cost of Goods Sold | $2,724 | $3,417 | $2,525 | $3,483 |
| Gross Profit | -$1,510 | -$2,564 | $4,099 | -$2,763 |
| % Margin | -124.4% | -300.6% | 61.9% | -383.8% |
| R&D Expenses | $2,571 | $1,368 | $1,532 | $3,292 |
| G&A Expenses | $0 | $10,917 | $0 | $10,917 |
| SG&A Expenses | $7,671 | $8,432 | $9,036 | $10,917 |
| Sales & Mktg Exp. | $0 | -$2,485 | $0 | $0 |
| Other Operating Expenses | $0 | $0 | $3,600 | $0 |
| Operating Expenses | $10,242 | $9,800 | $14,168 | $14,209 |
| Operating Income | -$11,752 | -$12,364 | -$10,069 | -$36,972 |
| % Margin | -968% | -1,449.5% | -152% | -5,135% |
| Other Income/Exp. Net | -$6,148 | $12,351 | -$10,375 | -$7,656 |
| Pre-Tax Income | -$17,900 | -$13 | -$20,444 | -$44,628 |
| Tax Expense | $0 | $0 | $0 | $0 |
| Net Income | -$17,900 | -$13 | -$20,444 | -$44,628 |
| % Margin | -1,474.5% | -1.5% | -308.6% | -6,198.3% |
| EPS | -0.73 | -0.001 | -0.97 | -5.18 |
| % Growth | -145,900% | 99.9% | 81.3% | – |
| EPS Diluted | -0.73 | -0.001 | -0.97 | -5.18 |
| Weighted Avg Shares Out | 24,585 | 23,919 | 21,167 | 8,609 |
| Weighted Avg Shares Out Dil | 24,585 | 23,919 | 21,167 | 8,609 |
| Supplemental Information | – | – | – | – |
| Interest Income | $196 | $346 | $515 | $300 |
| Interest Expense | $2,014 | $2,067 | $2,058 | $2,008 |
| Depreciation & Amortization | $493 | $474 | $498 | $835 |
| EBITDA | -$15,393 | $2,528 | -$17,888 | -$36,972 |
| % Margin | -1,268% | 296.4% | -270% | -5,135% |